Beyond breast cancer: role of selective estrogen receptor modulators in reducing systemic malignancies: evidence from population-based data.

SERM therapy administration is associated with a decreased incidence of cervical, ovarian, and colorectal cancers. Notably, the effects of raloxifene and bazedoxifene were consistent. Further investigations are crucial to elucidate the mechanisms underlying these observations and their clinical implications.